Abstract
Electroconvulsive therapy (ECT) is an effective treatment for depressive disorders. In certain cases, ECT-associated anaesthesia can be improved by the use of ketofol (i.e., S-ketamine + propofol). We aimed to evaluate the empirical mixing ratio of ketofol in these cases for better clinical implementation. We retrospectively investigated n = 52 patients who received 919 ECT sessions with S-ketamine plus propofol as anaesthetic agents. Several anaesthesia and ECT-related parameters including doses of S-ketamine and propofol were analysed. The mean empirically determined S-ketamine/propofol ratio was 1.38 (SD ± 0.57) for 919 individual ECT sessions and 1.52 (SD ± 0.62) for 52 patients, respectively. The mean relative dose was 0.72 (± 0.18) mg/kg S-ketamine and 0.54 (± 0.21) mg/kg propofol. Higher propofol dose was associated with poorer seizure quality. Seizure quality and time in recovery room were significantly influenced by age. Ketofol could be an option to exploit the advantageous qualities of S-ketamine and propofol, if both doses are reduced compared with single use of S-ketamine or propofol. Patients with poor seizure quality may benefit from lower propofol doses, which are applicable by the addition of ketamine. An empirically determined mixing ratio in favour of ketamine turned out to be preferable in a clinical setting. Recovery time was primarily prolonged by higher age rather than by ketamine dose, which had previously often been associated with a prolonged monitoring time in the recovery room. These new findings could improve electroconvulsive therapy and should be replicated in a prospective manner.
Highlights
In 2015, depressive disorders affected 322 million people worldwide, representing 4.4% of the world’s population [1]
This paper aims to narrow this gap in research by empirically evaluating a more favourable mixing ratio of ketofol to optimize future anaesthesia in Electroconvulsive therapy (ECT)
Using data from all 919 ECT sessions resulted in a mean empirical S-ketamine/propofol ratio of 1.38 (SD ± 0.57), whereas a ratio of 1.52 (SD ± 0.62) was calculated using collapsed data (n = 52)
Summary
In 2015, depressive disorders affected 322 million people worldwide, representing 4.4% of the world’s population [1]. Anaesthesia is an indispensable part of ECT treatment to avoid awareness of muscle relaxation, which in turn is needed to prevent injuries caused by motor seizure [4]. The main hypnotic agents applied in ECT anaesthesia are barbiturates, etomidate, propofol and ketamine. Different characteristics of each agent can influence ECT effectivity and/or tolerability [5]. Apart from ketamine and etomidate, all aforementioned agents possess anticonvulsive properties [5,6]. In numerous studies propofol yielded the shortest seizure durations [7] and inferior effectiveness [8], yet it was associated with a better cardiovascular tolerability [9]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: European Archives of Psychiatry and Clinical Neuroscience
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.